Trump Administration to Announce New Round of Drug Pricing Agreements, Including Bayer and Takeda
nashnova research
Trump is expected to unveil new pricing agreements with Bayer, Takeda, and CSL on August 31, extending the "most-favored-nation" drug pricing framework — but smaller drugmakers remain reluctant, and the actual savings are far from certain.
Which companies are joining this round?
The White House says Germany's Bayer, Japan's Takeda, and Australia's CSL, along with several mid-size biotech firms, are expected to participate.
Bayer and Takeda both declined to comment; CSL did not immediately respond.
This means → the lineup is not fully locked in, and companies are staying quiet ahead of the formal announcement.
How does "most-favored-nation" pricing actually work?
Most-favored-nation pricing — bringing U.S. drug prices down to levels in other developed countries — is a framework Trump launched last year with 17 major drugmakers including Pfizer, Eli Lilly, and Amgen.
Participating companies agree to cut prices and sell certain drugs directly to patients through a Trump-branded website, in exchange for tariff exemptions.
In plain terms = drugmakers trade "lower prices + direct sales" for "no tariffs" — a deal that is part commercial, part political.
How much more do Americans actually pay?
U.S. patients typically pay nearly three times what patients in other developed countries pay for prescription drugs.
The administration is positioning this round as a key showcase of healthcare reform ahead of the midterm elections.
This reflects a policy timeline tightly tied to the electoral cycle — the timing is deliberate, not coincidental.
Why are smaller drugmakers reluctant to join?
Reuters previously reported that mid-size and smaller drugmakers show notably low enthusiasm for the deals.
As of June, only Japan's Astellas had confirmed an application; executives at firms like Ionis Pharmaceuticals said the financial upside is limited.
This means → for large pharma, tariff exemptions are valuable enough to justify price cuts; for smaller companies, the math simply does not add up.
Can the projected savings be trusted?
The Trump administration claims the overall drug pricing push could save federal and state governments roughly $64.3 billion over ten years.
That figure carries significant uncertainty — Medicaid, the federal program covering low-income patients, already secures steep discounts from drugmakers under existing law.
In plain terms = most Medicaid patients already pay very little out of pocket, so how much *additional* savings these new deals deliver on top of existing discounts is something no one can yet pin down.
市场有风险，内容仅供研究参考，不构成投资建议。